Sepsis is a major cause of death and disability. The Centers for Medicare & Medicaid Services (CMS) aims to improve sepsis outcomes through the Severe Sepsis and Septic Shock Management Bundle (S
READ MORE
Pancreatic stone protein (PSP), C-reactive protein (CRP), and procalcitonin (PCT) are potential biomarkers for early detection of infection and sepsis in critically ill patients. A
READ MORE
The complexity of clinical trials in critical illness remains a significant challenge. A discussion at the ISICEM Congress in Brussels focused on why trials often fail, the role of heteroge
READ MORE
Sepsis is a common and potentially fatal condition, causing over 270,000 deaths annually in the U.S. Emergency treatment involves fluids and vasopressors, with norepinephrine as the first-line choice
READ MORE
Early recognition and treatment of sepsis are crucial for improving patient outcomes, leading to clinical guidelines recommending sepsis screening programmes. However, evidence supporting these progr
READ MORE
Sepsis is a major cause of mortality worldwide, with intravenous crystalloid infusion being the first-line treatment to maintain organ perfusion. However, fluid overload is associated with poor...
READ MORE
Sepsis is a major but often overlooked cause of death and disability. In 2017, there were an estimated 48.9 million cases of sepsis, causing 11 million deaths worldwide. Sepsis is more comm
READ MORE
Sepsis, as defined by Sepsis-3, is a life-threatening organ dysfunction caused by a dysregulated response to infection, with high mortality rates, especially in septic shock. Sepsis can cause acute...
READ MORE
Vasopressors are commonly used in critically ill patients to increase vascular tone in cases of severe hypotension with signs of altered tissue perfusion, such as poor skin perfusion, altered mental...
READ MORE
Dementia is a progressive neurodegenerative disease with growing public health and economic implications. In 2019, 57.4 million people had dementia worldwide, a number projected to reach 152.8 millio
READ MORE
